{"id":"W3212299214","doi":"10.1182/blood-2021-152561","title":"Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Tolerability; Internal medicine; Adverse effect; Nilotinib; Imatinib mesylate; Imatinib; Myeloid leukemia; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005052175,0.0008783319,0.001669276,0.0005197377,0.00008526721,0.000113763,0.0003539357,0.0003349991,0.000184245],"category_scores_gemma":[0.0003412449,0.0007925142,0.00007948272,0.001143649,0.0001793574,0.0005410207,0.0007833064,0.000891388,0.00002906156],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006225072,"about_ca_system_score_gemma":0.00335048,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002723695,"about_ca_topic_score_gemma":0.02404283,"domain_scores_codex":[0.9936332,0.0003793713,0.002118047,0.001890599,0.0008960123,0.001082774],"domain_scores_gemma":[0.996997,0.0002992021,0.0005466804,0.001509464,0.0002261411,0.0004214966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3248995,0.2271413,0.3887914,0.001234054,0.001456207,0.0147676,0.01169619,0.0001171815,0.006856041,0.000001557235,0.0002587915,0.02278017],"study_design_scores_gemma":[0.660731,0.01243854,0.3094126,0.004730678,0.0006260668,0.0000137755,0.0002520024,0.0005635942,0.009830209,0.000001439384,0.0007689468,0.0006311911],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895521,0.003103411,0.000001445456,0.000204031,0.0001981306,0.006043833,0.0008142951,0.00004660793,0.00003616976],"genre_scores_gemma":[0.9970999,0.0003673098,0.000430647,0.0001311469,0.0002170591,0.0006983834,0.0008372423,0.0001416531,0.0000766608],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3358314,"threshold_uncertainty_score":0.9994526,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01260281943940314,"score_gpt":0.278387262362273,"score_spread":0.2657844429228698,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}